Optimizing the Schedule of PARP Inhibitors in Combination with (177)Lu-DOTATATE: A Dosimetry Rationale

(177)Lu-DOTATATE for neuroendocrine tumours is considered a low-toxicity treatment and may therefore be combined with other pharmaceuticals to potentiate its efficacy. One approach is to add a poly-[ADP-ribose]-polymerase (PARP) inhibitor to decrease the ability of tumour cells to repair (177)Lu-ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Hallqvist, Andreas, Svensson, Johanna, Hagmarker, Linn, Marin, Ida, Rydén, Tobias, Beauregard, Jean-Mathieu, Bernhardt, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615768/
https://www.ncbi.nlm.nih.gov/pubmed/34829796
http://dx.doi.org/10.3390/biomedicines9111570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615768/
https://www.ncbi.nlm.nih.gov/pubmed/34829796
http://dx.doi.org/10.3390/biomedicines9111570

Ejemplares similares